CLINICAL AND TRANSLATIONAL RESEARCH CENTER (CTRC) The Clinical and Translational Research Center (CTRC) is the dedicated MD Anderson site for complex biologically-based new drug evaluation. With its 32-room nursing treatment center and adjacent full-function research laboratory, the CTRC is an ideal location to perform intensive clinical trials with a focus on first-in- human, phase I, and phase II studies requiring rigorous time points and pharmacologic testing. The CTRC provides a distinct resource for physician-scientists and clinical investigators to develop new agents for cancer treatment by offering coordination of multidisciplinary research, regulatory compliance, budget development, intensive and time-sensitive monitoring of patients, phlebotomy, and prompt and accurate specimen processing, storage, tracking, and shipment. The CTRC director, Filip Janku, MD, PhD; co-director, Daniel Karp, MD; clinical administrative director, Brenda Brown, MSN, RN, OCN, NEA-BC; and assistant director, Passion Lockett, DrPH, CCRC, provide leadership through planning, directing, and coordinating the integration of services and transfer of knowledge between the CTRC and the other CCSG cores. Current services include biospecimen collection and processing ranging from basic pharmacokinetic sampling to cell isolation and enumeration. Major equipment includes 15 centrifuges, a biosafety cabinet, 6 ultra-low freezers, a cell culture analyzer, and an AeroScout freezer monitoring system. Demand for services has increased by 98% since the previous grant cycle, and the CTRC has met this demand by increasing efficiency and increasing capacity by expanding from 18 beds to 32. Over the 6-year period, the CTRC facilitated 193 cancer center members who produced 184 publications, with 92 (50%) in journals with IF >5 and 38 (21%) in journals with IF >10, including N Engl J Med, Lancet, Nature, Nat Med, J Clin Oncol, and Cancer Cell. The CTRC's total operating budget in the current grant year (Yr43) is $5,050,892, and the CCSG accounts for 4% ($213,297). A total of ~$600,000 was provided for research equipment ($55,402) and renovations. In Yr42, 110 cancer center members used the CTRC, and 55% of all usage was by peer review-funded users. All CCSG programs used the CTRC, with 38% of all usage by the Developmental Therapeutics Program, followed by the Stem Cell Transplantation and Cellular Therapy Program (13%). In Yr44, 4% ($218,178) is requested from the CCSG. The CTRC Specific Aims are:
Aim 1 : To leverage the infrastructure and support for transformative high-impact early-phase clinical trials;
Aim 2 : To develop, customize and implement a new clinical trials management system to increase efficiency, accountability, transparency, plus data and sample integrity;
Aim 3 : To implement tools to evaluate patients' satisfaction and deliver patient-centered clinical research;
and Aim 4 : To provide expertise, training and education to research staff, faculty, and trainees.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Romano, Gabriele; Chen, Pei-Ling; Song, Ping et al. (2018) A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8:556-567
Dray, Beth K; Raveendran, Muthuswamy; Harris, R Alan et al. (2018) Mismatch repair gene mutations lead to lynch syndrome colorectal cancer in rhesus macaques. Genes Cancer 9:142-152
Keene, Kimberly S; King, Tari; Hwang, E Shelley et al. (2018) Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 4:34
Zhang, Miao; Adeniran, Adebowale J; Vikram, Raghunandan et al. (2018) Carcinoma of the urethra. Hum Pathol 72:35-44
Ciurea, Stefan O; Bittencourt, Maria Cecilia Borges; Milton, Denái R et al. (2018) Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv 2:2254-2261
Chiu, Hua-Sheng; Somvanshi, Sonal; Patel, Ektaben et al. (2018) Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep 23:297-312.e12
Zhang, Yu; Zoltan, Michelle; Riquelme, Erick et al. (2018) Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology 155:210-223.e3
Hunt, Brady; Fregnani, José Humberto Tavares Guerreiro; Schwarz, Richard A et al. (2018) Diagnosing Cervical Neoplasia in Rural Brazil Using a Mobile Van Equipped with In Vivo Microscopy: A Cluster-Randomized Community Trial. Cancer Prev Res (Phila) 11:359-370
Taylor, Alison M; Shih, Juliann; Ha, Gavin et al. (2018) Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33:676-689.e3
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902

Showing the most recent 10 out of 12418 publications